Breast

FDA Approves First Cancer Drug Through New Oncology Review Pilot That Enables Greater Development Efficiency

(FDA.gov) July 18, 2018 - The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

read press release

An Earlier Dinner May Lower Risk Of Some Cancers, Study Says

(CNN) July 17, 2018 - People who eat dinner before 9 p.m. -- or at least two hours before going to sleep -- have a 20% lower risk of breast and prostate cancer than those who eat after 10 p.m. or go to bed shortly after supper, researchers found.

read article

Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

(Puma) July 17, 2018 - Puma Biotechnology, Inc., a biopharmaceutical company, and Strata Oncology, Inc., a precision oncology company, have entered into a collaborative agreement to accelerate patient enrollment in Puma’s ongoing Phase II SUMMIT trial of PB272 (neratinib).

read corporate press release

FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

(NASDAQ) July 18, 2018 - Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease.

read article

BioScent K9 Launches Program Using Canines to Provide Free Breast Cancer Screening for the Less Fortunate on SniffingOutCancer.org

(Morningstar) July 17, 2018 - BioScent K9, a Florida not-for-profit, announced today the launch of a program that will leverage specially-trained dogs to provide free breast cancer screening for women in need.

read article

Breast Cancer Follow-Up Imaging Varies Widely, Study Finds

(UCSF) July 13, 2018 - Follow-up imaging for women with non-metastatic breast cancer varies widely across the country, according to a new study led by researchers at UC San Francisco.

read article

Massive Genome Havoc in Breast Cancer is Revealed

(CSHL) July 12, 2018 - In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that have evolved to regulate cell growth.

read press release

Applying 'Already Done' Science to Cancer Control

(MedPage Today) July 11, 2018 - A fourth of cancer deaths in the U.S. would not occur if everyone had the same cancer mortality as college-educated Americans, authors of an American Cancer Society (ACS) study reported.

read article (free registration required)

Promising Clinical Trial Results Of Tucatinib With T-DM1 Against HER2+ Breast Cancer

(UCCC/Colorado Cancer Blogs) July 10, 2018 - Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer.

read article

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

(Celgene) July 10, 2018 - Celgene Corporation today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS). This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced triple negative breast cancer (TNBC), a type of breast cancer with high unmet need.

read corporate press release

Sometimes Patients Simply Need Other Patients

(New York Times/Associated Press) July 9, 2018 - When Jodie Ofosuhene learned she had breast cancer at age 29 in 2016, she got more than standard medical care.

read article

Computer Simulation Suggests Risk-Based Breast Screening Could Have Benefits

(Cancer Research UK) July 6, 2018 - When it comes to breast cancer screening, there’s a delicate balance between the benefits and harms.

read article

New Approach To Breast Cancer Screening — Tailoring Guidelines For Each Patient — May Save Lives And Money, Study Says

(STAT) July 5, 2018 - Preventive care experts have been divided for years on how to best counsel women on when to get breast cancer screenings. But a new study suggests that women might benefit from individualized approaches to mammograms rather than from universal guidelines.

read article

First Opinion: Opioid Stigma Is Keeping Many Cancer Patients From Getting The Pain Control They Need

(STAT) July 6, 2018 - History is repeating itself. Twenty years ago, a pain management crisis existed. As many as 70 percent of cancer patients in treatment at that time, or in end-of-life care, experienced unalleviated pain.

read article

Breast Cancer Surgeons Don't Always Order Genetic Testing For Patients

(Reuters Health) July 3, 2018 - Many breast cancer patients may miss out on genetic tests that could help pinpoint the ideal treatment regimen at least in part because their surgeons are uncomfortable discussing the pros and cons of these tests, a U.S. study suggests.

read article

Surgeons Influence Receipt of Genetic Testing After Breast Cancer Diagnosis

(University of Michigan) July 3, 2018 - Studies have shown that only about half of women diagnosed with breast cancer who could benefit receive genetic testing. A new study finds that surgeons are a key influence.

read article

New ‘Triple Therapy’ Could Boost Treatment And Prevent Relapse Of Advanced Breast Cancer

(ICR [UK]) July 3, 2018 - Treating advanced breast cancer with three drugs instead of one could boost the effectiveness of treatment and stop tumours developing resistance, a new study reports.

read article

Nanoparticles Open Doors To Cancer-Fighting CAR T Cells

(Fred Hutch News Service) July 2, 2018 - Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy.

read article

Phase III IMpassion130 Study Showed Roche’s Tecentriq Plus Abraxane Significantly Reduced The Risk Of Disease Worsening Or Death In People With Metastatic Triple Negative Breast Cancer

(Roche) July 2, 2018 - First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple negative breast cancer (TNBC) populations. Encouraging overall survival (OS) benefit for PD-L1 positive population at interim analysis.

read corporate press release

Roche 'Highly Encouraged' By Tecentriq Results In Breast Cancer

(Reuters) July 2, 2018 - Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

read article
Next Page